JP5031567B2 - 酵素阻害剤およびその使用 - Google Patents

酵素阻害剤およびその使用 Download PDF

Info

Publication number
JP5031567B2
JP5031567B2 JP2007530547A JP2007530547A JP5031567B2 JP 5031567 B2 JP5031567 B2 JP 5031567B2 JP 2007530547 A JP2007530547 A JP 2007530547A JP 2007530547 A JP2007530547 A JP 2007530547A JP 5031567 B2 JP5031567 B2 JP 5031567B2
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
aryl
irap
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007530547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512395A5 (cg-RX-API-DMAC7.html
JP2008512395A (ja
Inventor
シュー・イーン・チャイ
マイケル・ウィリアム・パーカー
アンソニー・ロイド・アルビストン
クレイグ・ジェイ・モートン
ホーイ・リン・ン
シイン・イェ
フレデリック・エイ・オー・メンデルソーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Florey Institute of Neuroscience and Mental Health
Original Assignee
Howard Florey Institute of Experimental Physiology and Medicine
St Vincents Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by Howard Florey Institute of Experimental Physiology and Medicine, St Vincents Institute of Medical Research filed Critical Howard Florey Institute of Experimental Physiology and Medicine
Publication of JP2008512395A publication Critical patent/JP2008512395A/ja
Publication of JP2008512395A5 publication Critical patent/JP2008512395A5/ja
Application granted granted Critical
Publication of JP5031567B2 publication Critical patent/JP5031567B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2007530547A 2004-09-09 2005-09-09 酵素阻害剤およびその使用 Expired - Fee Related JP5031567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004905182 2004-09-09
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
PCT/AU2005/001380 WO2006026832A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2008512395A JP2008512395A (ja) 2008-04-24
JP2008512395A5 JP2008512395A5 (cg-RX-API-DMAC7.html) 2008-10-23
JP5031567B2 true JP5031567B2 (ja) 2012-09-19

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007530547A Expired - Fee Related JP5031567B2 (ja) 2004-09-09 2005-09-09 酵素阻害剤およびその使用

Country Status (13)

Country Link
US (1) US20080194636A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789079B1 (cg-RX-API-DMAC7.html)
JP (1) JP5031567B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070100878A (cg-RX-API-DMAC7.html)
CN (1) CN101039690A (cg-RX-API-DMAC7.html)
CA (1) CA2579768A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789079T3 (cg-RX-API-DMAC7.html)
ES (1) ES2403340T3 (cg-RX-API-DMAC7.html)
IL (1) IL181819A (cg-RX-API-DMAC7.html)
NZ (1) NZ553688A (cg-RX-API-DMAC7.html)
SG (1) SG155901A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006026832A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702041B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
PL3150581T3 (pl) 2014-05-28 2020-07-13 Astellas Pharma Inc. Pochodne pirydyny
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
WO2017015720A1 (en) 2015-07-30 2017-02-02 Monash University Fibrotic treatment
WO2023099589A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
US20050020519A1 (en) * 2001-08-02 2005-01-27 Albiston Anthony L. Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
PL372488A1 (en) * 2002-02-13 2005-07-25 F.Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079B1 (en) 2012-11-07
US20080194636A1 (en) 2008-08-14
EP1789079A4 (en) 2010-09-01
SG155901A1 (en) 2009-10-29
IL181819A (en) 2013-07-31
JP2008512395A (ja) 2008-04-24
EP1789079A1 (en) 2007-05-30
NZ553688A (en) 2011-05-27
CN101039690A (zh) 2007-09-19
ZA200702041B (en) 2008-09-25
CA2579768A1 (en) 2006-03-16
WO2006026832A1 (en) 2006-03-16
DK1789079T3 (da) 2013-03-11
ES2403340T3 (es) 2013-05-17
KR20070100878A (ko) 2007-10-12

Similar Documents

Publication Publication Date Title
AU2007262670B2 (en) Method of treatment of glioma brain tumour
ES2425567T3 (es) Método de tratamiento o profilaxis
US8377963B2 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
JP6991993B2 (ja) 痛覚過敏を治療する方法
JP7457360B2 (ja) 線維症の処置
JP2011523647A (ja) カルシウムチャネルブロッカーとしてのn−ピペリジニルアセトアミド誘導体
MX2007000793A (es) Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecanica.
TW201841637A (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
Fukabori et al. Enhanced retrieval of taste associative memory by chemogenetic activation of locus coeruleus norepinephrine neurons
EP1789079B1 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
JP2022500445A (ja) Gabaa受容体リガンド
US20050119461A1 (en) Novel receptor, and compounds which bind thereto
AU2005282229B2 (en) Enzyme inhibitors and uses thereof
US20180170891A1 (en) 4H-Pyran Compounds as Insulin-Regulated Aminopeptidase (IRAP) Inhibitors
JP2022554159A (ja) Gabaa受容体モジュレーターによるてんかん状態の治療
WO2022031407A1 (en) Gpr101 ligands for treating growth hormone-related disorders
US20090010909A1 (en) Novel GPCR and methods of use of the same
AU2007234577A1 (en) Novel compounds and uses thereof
CA2611072A1 (en) Novel compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120619

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120627

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150706

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees